Oral molecular glue degrader with or without spartalizumab shows immune activation and tumour control in solid tumours

ctDNA positivity predicts poor response and recurrence risk in triple-negative breast cancer

Daraxonrasib plus chemotherapy shows promising first-line activity in RAS-mutant metastatic pancreatic cancer

ZL-1310 shows promising activity in DLL3-positive neuroendocrine carcinomas

DLL3 expression in circulating tumour cells predicts response to tarlatamab in small cell lung cancer

Tumour-selective oncolytic adenovirus LOAd703 with chemo shows immune activation and promising responses in pancreatic cancer

Oncolytic adenovirus VCN-01 plus chemo shows promising survival benefit in metastatic pancreatic cancer

Trastuzumab and tucatinib enable organ preservation in HER2-positive rectal cancer

Rilvegostomig clears ctDNA and delays recurrence in high-risk head and neck cancer

Setidegrasib shows promising activity in KRAS G12D-mutated advanced NSCLC

mCRPC treatment sequencing: Need for optimal therapy at the earliest opportunity

The potential of T-cell engagers in SCLC treatment